Yamada Shinsuke, Inaba Masaaki, Nishizawa Yoshiki
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine.
Clin Calcium. 2004 Apr;14(4):573-9.
On the progress of study concerned with pathology of metabolic bone disease such as osteoporosis, it has been known that most of bone strength can be explained by bone volume. As bone volume can be determine by bone mineral density (BMD) with dual-energy X-ray absorptiometry (DXA), it has been widely used for diagnosis of osteoporosis or efficacy of treatment. However, with the advance of bone morphometry, decrease of bone strength or existence of insufficiency fracture is influenced by not only loss of BMD but also deterioration of bone quality especially bone microstructure. In this chapter, we will give an outline of change of bone quality in metabolic bone disease.
关于骨质疏松症等代谢性骨病病理学相关研究的进展,人们已经知道,大部分骨强度可以用骨体积来解释。由于骨体积可以通过双能X线吸收法(DXA)测量骨密度(BMD)来确定,因此它已被广泛用于骨质疏松症的诊断或治疗效果评估。然而,随着骨形态计量学的发展,骨强度的降低或不全骨折的存在不仅受骨密度降低的影响,还受骨质量尤其是骨微结构恶化的影响。在本章中,我们将概述代谢性骨病中骨质量的变化。